We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Decoding Microbial Shifts in Postoperative Crohn’s Disease: Insights into Recurrence Dynamics

MedXY Editorial Team•Jul 10, 2026•Gastroenterology
16S rRNA sequencingCrohn’s diseasemucosa-associated microbiotaRutgeerts score术后复发

Highlight

  • Postoperative recurrence of Crohn’s disease involves distinct shifts in the mucosa-associated microbiota, notably decreases in Faecalibacterium prausnitzii and increases in Akkermansia muciniphila.
  • The Rutgeerts score, measuring endoscopic recurrence severity, relates to specific microbial signatures, emphasizing the value of multilevel microbiota analysis rather than binary classification.
  • Network analysis reveals a denser microbial community after surgery in patients without recurrence, indicating dynamic ecosystem reorganization related to disease status.
  • The study integrates microbial compositional changes with clinical outcomes, advancing our understanding of post-ileal resection Crohn’s disease pathophysiology.

Study Background

Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease affecting the gastrointestinal tract, frequently requiring surgical intervention. Approximately 50% to 75% of patients with CD undergo bowel resection during their disease course to manage complications or refractory inflammation. However, postoperative recurrence is a well-recognized challenge, typically assessed endoscopically using the Rutgeerts score, which grades inflammation severity at the neo-terminal ileum and anastomosis. Despite its clinical importance, the pathophysiological processes underpinning microbiota changes in the postoperative mucosa and their relationship to recurrence remain inadequately understood. Unraveling these microbial dynamics could inform prophylactic and therapeutic strategies to prevent recurrence.

Study Design

This multicenter study by Dubois et al. profiled mucosa-associated microbiota in CD patients undergoing ileal resection. Biopsies from 139 subjects were sampled at the time of surgery (M0) and from 125 subjects during follow-up endoscopic surveillance 6 months postoperatively (M6). The Rutgeerts score was employed to stratify recurrence severity, capturing a gradient of mucosal inflammation. Microbial profiling utilized 16S ribosomal RNA gene sequencing for bacteria and ITS2 sequencing for fungal communities. Analytical approaches included relative abundance comparisons adjusted for clinical covariates, machine learning for predictive modeling, and community ecology network analyses to explore microbial interactions and keystone species dynamics.

Key Findings

The study revealed that while surgery and recurrence exerted moderate overall effects on microbial community composition, specific taxa exhibited significant differential abundance linked to recurrence grades.

Notably, the anti-inflammatory commensal Faecalibacterium prausnitzii showed diminished abundance correlating with higher Rutgeerts scores and increased mucosal inflammation. Conversely, Akkermansia muciniphila – a mucin-degrading bacterium sometimes implicated in mucosal health and disease – increased as recurrence severity escalated. These taxa changes were compartmentalized, differing between inflammatory involvement at the anastomosis versus the ileum itself.

Importantly, machine learning models demonstrated enhanced predictive performance when the full spectrum of the Rutgeerts score was incorporated, underscoring the value of multilevel phenotyping beyond simple binary classifications (recurrence vs no recurrence).

Community network analysis uncovered a more tightly organized microbiota network post-surgery in patients without recurrence, indicating resilience and stability in microbial interactions. Keystone species within these networks altered dynamically in relation to recurrence status, revealing complex ecosystem remodeling during disease progression.

Expert Commentary

These findings align with growing evidence that mucosal microbial communities are intimately involved in CD pathology and postoperative disease behavior. Faecalibacterium prausnitzii has been consistently associated with anti-inflammatory effects through butyrate production; its depletion postoperatively likely contributes to mucosal vulnerability and recurrence. Meanwhile, the role of Akkermansia muciniphila is nuanced and may reflect attempts at mucosal healing or dysregulated mucin degradation.

The study’s comprehensive approach, integrating microbial profiling with clinical parameters and advanced analytical modeling, represents a methodological strength, yet limitations exist. These include the cross-sectional design at M6 limiting causal inference and potential confounders like antibiotic use or immunosuppressive therapy influencing microbiota.

Future longitudinal studies incorporating functional metagenomics and host immune profiling may further elucidate mechanistic pathways. These insights could pave the way for microbiota-targeted interventions, such as probiotics or fecal microbiota transplantation, tailored to modulate key microbial players and prevent recurrence.

Conclusion

This study advances our understanding of the dynamic mucosal microbiota landscape after ileal resection in Crohn’s disease and its association with postoperative recurrence. The data support a view of recurrence as a complex, multi-phasic process involving shifts in key microbial taxa and network structures. Importantly, leveraging the full range of endoscopic disease severity enhances microbiota-based predictive modeling.

Clinically, these insights highlight potential microbial biomarkers for early detection of recurrence risk and therapeutic targets to restore a protective microbiota ecosystem, ultimately aiming to improve postoperative outcomes in Crohn’s disease management.

Funding and ClinicalTrials.gov

The original study was conducted by a large collaborative group (REMIND Group) and published in Gastroenterology. Specific funding details are reported in the primary publication. No clinical trial registration was indicated for this observational microbiota profiling study.

References

Dubois L, Chaussard A, Seksik P, et al. Uncovering the Dynamics of Mucosa-Associated Microbiota in Postoperative Recurrence of Crohn’s Disease. Gastroenterology. 2026 Feb 24;171(1):84-98. PMID: 41747778.

Sokol H, Seksik P, Furet J-P, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183-9.

Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013 Jun;16(3):255-61.

Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008 May 29;453(7195):620-5.

Borren NZ, van Nood E, Nieuwdorp M, et al. Fecal microbiota transplantation impacts on restoration of mucosal barrier function in inflammatory bowel disease. Therap Adv Gastroenterol. 2020;13:1756284820926334.

Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014 Aug;63(8):1275-83.

Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016 Jul 7;535(7610):75-84.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unveiling the TL1A-LTα1β2/IL-22 Axis: A New Therapeutic Target in Crohn’s Disease with Perianal Fistulising DiseaseThis study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis inSep 19, 2026Early Childhood Exposure to Crohn’s Disease-Affected Siblings: Implications for Gut Microbiome and Disease SusceptibilityChildhood exposure to siblings with Crohn’s disease significantly raises disease risk, linked to distinct gut microbiome changes that may drive disease onset through immune modulation.Aug 28, 2026WISP1 as a Therapeutic Target in Crohn’s Disease: Linking Metabolic Reprogramming to Intestinal FibrosisThis study reveals the pivotal role of WISP1 in driving intestinal fibrosis in Crohn’s disease through fibroblast metabolic shifts and cytoskeletal remodeling, suggesting WISP1 neutralization as a novel antifibrotic intervention.Aug 19, 2026New Insights into Artificial Sweeteners and Emulsifiers in Crohn’s Disease: Biomarkers and Metabolic Mechanisms from the ENIGMA Study
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
The ENIGMA study reveals altered metabolism of the emulsifier polysorbate-80 and elevated artificial sweeteners in Crohn’s disease, linking these dietary additives to disease activity and potential biomarker development.
Aug 14, 2026
Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE TrialThe REScUE study compared two ustekinumab dosing intensification regimens after secondary loss of response in Crohn’s disease, finding no superiority of more frequent dosing regarding steroid-free remission at 48 weeks.Jul 13, 2026
BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic AvenuesRare variants in the BIRC3 gene cause defective regulation of RIPK1 signaling, leading to increased intestinal epithelial cell death and monogenic Crohn’s disease. Targeting RIPK1 offers a promising therapeutic strategy.Jun 27, 2026